NCT04365101 (CYNKCOVID) is a Phase 1, PHASE2 clinical trial of CYNK-001 in Coronavirus, sponsored by Celularity Incorporated.

Who is sponsoring NCT04365101?

NCT04365101 is sponsored by Celularity Incorporated.

What drugs are being tested in NCT04365101?

Interventions in NCT04365101: CYNK-001.

What condition does NCT04365101 study?

NCT04365101 studies Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic.

Is NCT04365101 still recruiting?

NCT04365101 is currently status unknown. Last updated 25 May 2022.

Last reviewed 2022-05-25 · How we verify

NCT04365101: CYNKCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Status unknown Phase 1, PHASE2 Last updated 25 May 2022

What this trial tests

Phase 1, PHASE2 trial testing CYNK-001 in Coronavirus in 86 participants. Status unknown.

Timeline

13 May 2020

Primary endpoint
30 December 2021

30 June 2022

Quick facts

Lead sponsor	Celularity Incorporated
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	86
Start date	13 May 2020
Primary completion	30 December 2021
Estimated completion	30 June 2022
Sites	7 locations across United States

Drugs / interventions tested

CYNK-001 — full drug profile →

Conditions studied

Coronavirus — all drugs for Coronavirus →
Coronavirus Infection — all drugs for Coronavirus Infection →
Severe Acute Respiratory Syndrome Coronavirus 2 — all drugs for Severe Acute Respiratory Syndrome Coronavirus 2 →
Pneumonia — all drugs for Pneumonia →

Sponsor

Celularity Incorporated — full company profile →

Who can join

18 and older, any sex, with Coronavirus or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M, Angka L, Martel AB, Bastin D, et al · · 2020 · cited 115× · PMID 32655581 · DOI 10.3389/fimmu.2020.01512
Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
Sarkar C, Mondal M, Torequl Islam M, Martorell M, et al · · 2020 · cited 64× · PMID 33041814 · DOI 10.3389/fphar.2020.572870
Immunobiology and immunotherapy of COVID-19: A clinically updated overview.
Esmaeilzadeh A, Elahi R. · · 2021 · cited 59× · PMID 33022076 · DOI 10.1002/jcp.30076
Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C, Calcaterra F, Coianiz N, Terzoli S, et al · · 2022 · cited 55× · PMID 35844604 · DOI 10.3389/fimmu.2022.888248
Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.
Gupta A, Kashte S, Gupta M, Rodriguez HC, et al · · 2020 · cited 55× · PMID 32780299 · DOI 10.1007/s13577-020-00407-w
Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S, Abdelalim EM. · · 2020 · cited 54× · PMID 33059757 · DOI 10.1186/s13287-020-01963-6
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.
Zuo W, Zhao X. · · 2021 · cited 51× · PMID 33887436 · DOI 10.1016/j.clim.2021.108727

Verify or expand the search:

Other trials of CYNK-001

Trials testing the same drug.

NCT04309084 — Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma · Phase 1 · unknown
NCT04310592 — Natural Killer Cell (CYNK-001) Infusions in Adults with AML · Phase 1 · terminated

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Celularity Incorporated trials

Trials by the same sponsor.

NCT05207722 — CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic · Phase 1, PHASE2 · terminated
NCT04489420 — Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM · Phase 1 · terminated
NCT04309084 — Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma · Phase 1 · unknown
NCT04310592 — Natural Killer Cell (CYNK-001) Infusions in Adults with AML · Phase 1 · terminated
NCT02955550 — A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Sub · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04365101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celularity Incorporated
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04365101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing